The Hidden Androgen Crisis in Australian Women

Why up to 3.5 million women are suffering from a hormonal deficiency that is systematically overlooked, misdiagnosed, and undertreated

When we talk about menopause, we talk about oestrogen. But the research tells a different story, one in which testosterone, long dismissed as a male hormone, sits at the centre of millions of women's unexplained fatigue, vanishing libido, brain fog, flat mood, and declining vitality. And almost no one is talking about it.

1. The Scale of the Problem in Australia

~7M

Australian women currently peri- or menopausal

80–90%

Will experience significant symptoms

2M+

Experience debilitating symptoms

>85%

With bothersome symptoms receiving NO effective treatment

63%

Of surveyed Australian women describe symptoms as severe or very severe

<7%

With genitourinary symptoms prescribed appropriate treatment

2. What Women Are Never Told About Testosterone

"Before menopause, women produce three times more testosterone than oestrogen. It is the dominant sex steroid by volume throughout a woman's reproductive life — yet it is almost never discussed."

The Androgen Family: Sources and Roles in Women

Androgen	Primary Source	Biologically Active?	Key Role
Testosterone (T)	Ovaries (25%), adrenals (25%), peripheral conversion (50%)	Yes — binds androgen receptors directly	Libido, energy, mood, cognition, bone, muscle, cardiovascular health
Dihydrotestosterone (DHT)	Peripheral conversion of T via 5α-reductase	Yes — most potent androgen	Tissue-level androgen activity; skin, hair follicles, genitourinary
DHEA	Adrenal glands (80%), ovaries (20%)	Prohormone — must convert to T or oestrogen	Precursor pool; mood, immune function, well-being
DHEAS	Almost exclusively adrenal	Prohormone — storage form of DHEA	Most abundant steroid in circulation; marker of adrenal function
Androstenedione (A4)	Adrenals and ovaries (roughly equal)	Prohormone — converts to T and oestrone	Key precursor; contributes to postmenopausal oestrogen via aromatisation
Androstenediol (Adiol)	Adrenal (rises sharply in perimenopause)	Yes — dual androgenic and oestrogenic activity	Critical perimenopausal buffer; may partially compensate for oestrogen loss

Only testosterone and DHT bind androgen receptors directly. All others require peripheral conversion to exert androgenic effects.

Testosterone Decline Across a Woman's Life (% of peak, population median)

Late 20s — Peak 100%

Peak

Age 35 ~75%

~75%

Age 40 ~50%

~50%

Perimenopause / Menopause ~40%

~40%

Age 58–60 (nadir) ~28%

~28%

Post-oophorectomy (from baseline) ~50% drop overnight

Acute loss

Davis et al., eBioMedicine 2025; SWAN study longitudinal data. LC-MS/MS measurement.

3. The Hormonal Cascade — What Should Happen, and What Goes Wrong

Late 30s → Early 40s

Progesterone falls first. Cycles become anovulatory. The midcycle testosterone surge — which drives libido at peak fertility — disappears. Oestradiol fluctuates unpredictably, often surging above premenopausal levels before eventually declining.

Perimenopause (avg. 47–51)

In 85% of women: the adrenal glands mount a compensatory rise in androgens — DHEA and androstenediol can rise 5–8 fold above premenopausal levels. This acts as a partial buffer against oestrogen withdrawal, helping protect mood, energy, bone, and cognition during the transition.

The Critical 15%

~1 million Australian women receive NO adrenal buffer. Both oestrogen and androgens fall simultaneously. These women face the steepest hormonal cliff — and are the most severely symptomatic. They are largely invisible to current clinical systems.

Post-Menopause

The postmenopausal ovary remains active, contributing 40–50% of testosterone production for up to 10 years. Natural menopause does not cause a sudden testosterone crash. Surgical removal of the ovaries does — dropping levels ~50% overnight.

Hormonal Changes Across the Full Menopausal Transition

Phase	Oestradiol	Progesterone	Testosterone	Adrenal Androgens	Net Hormonal Effect
Reproductive prime (20s–30s)	Cyclic, adequate	Cyclic post-ovulation	Declining from peak	Peaking then declining	Hormonal sufficiency
Late reproductive / early peri (late 30s–40s)	Fluctuating, surging	Falling (anovulation)	~50% of peak by 40	Beginning to rise (SWAN)	Relative androgen loss underway
Mid-perimenopause	Wild fluctuation	Very low	Declining	Rising (85% of women)	Buffer in most; severe symptoms in 15%
Late peri / menopause	Collapsing	Near zero	Partly maintained (ovarian)	Peaking then declining	Relative androgenicity; oestrogen dominant loss
Early post-menopause	Very low	Zero	Ovary still contributes 40–50%	Declining	High T:E2 ratio; bone/CV/genitourinary risk
Late post-menopause (10+ yrs)	Very low	Zero	Progressively lower	Continuing decline	Full androgen insufficiency in many
Surgical menopause (oophorectomy)	Acute collapse	Zero	~50% immediate drop	Adrenal partially compensates	Most severe deficiency state

4. The Full Symptom Burden of Androgen Insufficiency

The symptoms below are frequently misattributed to depression, burnout, thyroid disorders, or oestrogen deficiency. Every single one overlaps with other conditions — which is precisely why androgen insufficiency goes undetected for so long.

Sexual Health

Absent or drastically low libido (HSDD)
Loss of sexual fantasies
Reduced arousal and orgasm
Diminished genital sensitivity
Vaginal dryness and dyspareunia

Energy & Vitality

Bone-deep exhaustion unrelieved by sleep
Blunted motivation and drive
Reduced exercise tolerance
Loss of ambition and competitive edge

Mood & Psychology

Dysphoric or persistently flat mood
Depression not responding to antidepressants
Anxiety and emotional fragility
Loss of confidence and identity
"Something is missing" — hard to name

Cognition

Brain fog and word-finding difficulty
Poor working memory
Slowed mental processing
Reduced focus and sharpness

Body & Bone

Sarcopenia — loss of muscle mass
Central weight gain
Osteopenia and osteoporosis
Thinning hair and dry skin
Loss of pubic and axillary hair

Cardiovascular & Metabolic

Loss of vascular nitric oxide protection
Association with adverse CV outcomes
Accelerated atherosclerosis post-oophorectomy
Increased central adiposity and metabolic risk

Symptom Prevalence in Peri/Menopausal Women

Symptom	Prevalence	Primary Hormone Driver	Androgen Component?
Hot flushes / night sweats	70–80%	Oestrogen withdrawal	Partial — T:E2 ratio worsens bother
Sleep disturbance / exhaustion	~85% find difficult	Oestrogen + vasomotor	Yes — testosterone supports energy and sleep quality
Low libido / HSDD	40–50%	Testosterone primary driver	Yes — primary androgen-sensitive symptom
Brain fog	~75% find difficult	Oestrogen + testosterone	Yes — androgen receptors in hippocampus and prefrontal cortex
Mood changes / depression	~40–45%	Oestrogen + testosterone	Yes — testosterone supports dopaminergic pathways
Vaginal dryness / dyspareunia	>50% post-menopause	Oestrogen primary	Yes — androgens have direct independent effect on vaginal epithelium
Muscle loss / weakness	Progressive with age	Testosterone primary	Yes — testosterone critical for lean body mass
Bone loss	Accelerates post-menopause	Oestrogen + testosterone	Yes — testosterone stimulates osteoblast activity directly
Fatigue / low motivation	Majority of symptomatic women	Testosterone prominent	Yes — second most common androgen-related complaint
Anxiety	~40% higher risk vs premenopause	Oestrogen fluctuation	Partial — DHEA may support GABAergic pathways

Sources: British Menopause Society; Statista / Fawcett Society UK survey (2022); PMC primary research. Prevalence data reflects peri/postmenopausal populations.5. Why It Gets Worse — Compounding Factors

Factors That Reduce Testosterone Bioavailability in Women

Factor	Mechanism	Impact on Free Testosterone	Affected Group
Oral oestrogen MHT (tablets)	First-pass liver metabolism → raises SHBG, binding free T	Significant reduction in bioavailable testosterone	Any woman on oral oestrogen MHT
Combined oral contraceptive pill	Suppresses ovarian function + raises SHBG	Significant reduction; SHBG elevation can persist after cessation	Women on combined OCP (current or recent)
Bilateral oophorectomy	Removes 40–50% of testosterone source	~50% acute drop in circulating testosterone	Women post-oophorectomy
Corticosteroids (oral)	Reduce adrenal and ovarian androgen production	Up to 75% reduction in total testosterone	Women on long-term steroid therapy
Chemotherapy / radiation	Ovarian damage; adrenal suppression	Significant; degree varies by treatment type	Cancer survivors
Opioids	Suppress HPG axis signalling	Moderate to significant reduction	Women on regular opioid therapy
Premature ovarian insufficiency	Early loss of ovarian androgen production	Significant reduction before expected natural decline	Women under 40 with POI
Adrenal insufficiency (Addison's)	Loss of adrenal androgen contribution	Significant reduction in DHEA/DHEAS and downstream T	Women with adrenal disease
Transdermal oestrogen MHT	Bypasses liver — minimal SHBG effect	Neutral — does not reduce free testosterone	Women on patches, gels, sprays

"A woman who starts oral MHT tablets to relieve menopausal symptoms may unknowingly suppress what little free testosterone she has left — worsening the fatigue, flat mood, and low libido the medication was meant to help."

6. The Treatment Gap: How Many Australian Women Need Support?

Estimated Australian Women with Androgen-Related Need vs. Those Currently Supported

All peri/menopausal women (age-related decline) ~7 million

~7M

Symptomatic androgen insufficiency cluster ~2.8–3.5M

~2.8–3.5M

Missing compensatory adrenal rise ~1M

~1M

Oral MHT with suppressed free testosterone ~200–400k

Post-oophorectomy androgen deficit ~150–250k

Currently receiving any testosterone support <5% of need

SWAN data; AMS guidelines; Medical Journal of Australia (2023); Balance Health AU; Menodoctor Australia Survey.

Why the Care Gap Is So Large: Barriers to Diagnosis and Treatment

Barrier	Detail	Impact
Symptom overlap	Every androgen insufficiency symptom mimics depression, burnout, thyroid disorders, and oestrogen deficiency	Misdiagnosis is the norm; women referred for antidepressants or CBT
Testing imprecision	Standard immunoassay tests cannot accurately measure the low testosterone concentrations in women	Deficiency missed or falsely excluded
SHBG not routinely measured	Total testosterone measured but free testosterone (the active fraction) rarely calculated	Women with normal total T but high SHBG appear "normal" but are functionally deficient
Intracrine activity invisible	~50% of androgen action occurs inside target tissues — not in circulating blood	Serum tests fundamentally miss tissue-level deficiency
Prescriber training gap	Menopause is not in the top 15 conditions managed by Australian GPs; ~80% of OB/GYNs lack formal menopause training	Women receive inappropriate or no treatment
Natural Medicines Awareness	Very few doctors and even natural medicine practitioners understand the importance of testosterone and how to boost it naturally.
Institutional inertia	The T–libido link was published in 1959; clinical guidelines took 40+ more years to emerge	Many women still told symptoms are "just part of ageing"
Cultural silence	1 in 2 Australian women go through menopause without consulting a health professional	Millions suffer in silence; self-manage with unproven supplements

"The science is established. The regulatory framework exists. The clinical need is undeniable. What's missing is access, awareness, and a practical solution that meets women where they are at.

References: Davis SR et al., eBioMedicine 2025 (Australian Women's Midlife Years Study, LC-MS/MS); SWAN Study longitudinal data (McConnell et al.); Medical Journal of Australia (2023) — Advancing menopause care in Australia; Australasian Menopause Society guidelines and MHT dose guide (Nov 2024); International Menopause Society White Paper 2024; British Menopause Society / NICE guidelines; Menodoctor Australia Survey (5,000+ women, 2024); Australian Government Response to Senate Inquiry on Perimenopause and Menopause, February 2025; Balance Health Australia population data; Wellbeing of Women / UCL population estimates; PMC/NIH primary research on adrenal androgens and menopausal transition (SWAN, Burger et al., Davey 2012); Fertility & Sterility (2002); Cleveland Clinic Journal of Medicine (2021).

Cart